Press Coverage

Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics (Royalty Pharma)

Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty interest in risdiplam for a one-time payment of $650 million.

Risdiplam, to be marketed by Roche, is an investigational, orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatment of spinal muscular atrophy (SMA). SMA is a severe, inherited, progressive neuromuscular disease that causes devastating muscle atrophy and disease-related complications. It is the most common genetic cause of infant mortality and one of the most common rare diseases, affecting approximately one in 11,000 babies.

[…]

Wilmer Hale acted as legal advisor to PTC Therapeutics on the transaction. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty Pharma.

This text is a press release from Royalty Pharma. The full text version of the article can be found here: https://www.royaltypharma.com/news-releases/news-release-details/royalty-pharma-acquires-royalty-interest-risdiplam-ptc

Newsletter